BridgeBio Neutral Stance From Citi Shakes ATTR-CM Outlook
Citi initiates BridgeBio at Neutral, signaling caution on ATTR-CM growth despite a strong near-term ramp. The move ad...
Understanding the differences between value and growth investing strategies is crucial for your investment approach. Discover more insights here.
25,836 articlesCiti initiates BridgeBio at Neutral, signaling caution on ATTR-CM growth despite a strong near-term ramp. The move ad...
Fluor dropped 26% and headlines lit up. But a solid long-term thesis for this EPC powerhouse requires more than a fla...
A new move from Google signals a shift in AI compute. This could tilt the balance away from Nvidia in certain cloud a...
A seismic shift is brewing in the card world. Capital One's integration with Discover could turn payment processing i...
Natera shows growth through AI-enabled cell-free DNA tests and a widening data moat, positioning it as a leading nate...
Caesars Entertainment moves to go private in a $17.6 billion deal, and investors are eyeing four lagging U.S. compani...
In 2025, Marathon Petroleum delivered a powerful cash-return story for shareholders. This article breaks down how the...
Ford famously pulled back from most sedans years ago. This article examines the strategic pivot, what a sedan comebac...
A Life360 board director recently sold several thousand shares after exercising options, timing that coincides with a...
A veteran investor argues that China’s full AI stack is underpriced as a major funding round and an upcoming Hong Kon...
TJX posted a strong fourth quarter ahead of expectations, yet conservative guidance sparked a pullback in shares as i...
Analysts publish an eyebrow-raising spacex’s $800 price target, implying a potential trillion-dollar leap in value an...